FDA药物基因组学关联表与CPIC指南的比较
本文比较了FDA药物基因组学关联表与CPIC指南中的基因-药物相互作用信息。两者一致性不高,126种药物中仅5种有相同的基因-药物关联和剂量推荐。FDA表特定分类与CPIC临床可操作性等级相关性不佳,信息源差异可能影响临床采纳。
要点
- FDA表与CPIC指南对基因-药物关联的覆盖和分类不一致,临床需结合两者使用。
- 仅5/126种药物在两者中具有相同的基因-药物关联和剂量推荐。
- PharmGKB临床注释等级在CPIC指南药物中通常较高,在仅FDA表药物中常未分配或较低。
核心结论
- FDA药物基因组学关联表与CPIC指南在基因-药物关联和剂量推荐上存在重要差异,两者评价视角和信息资源不同,需整合使用以形成全面观点。
研究设计与样本
- 比较性研究,比较FDA药物基因组学关联表与CPIC指南中的药物基因组学信息,涉及任一来源包含的126种药物。
主要发现
- CPIC指南和FDA表之间一致性不高,许多药物仅出现在一方,仅5/126种药物报告了相同的基因-药物关联和剂量推荐。
- FDA表特定部分的药物分类与CPIC分配或临时分配的临床可操作性等级相关性不佳。
- PharmGKB临床注释等级在CPIC指南提及的药物中通常较高,在仅FDA表列出的药物中常未分配或等级较低。
关键数值与推荐
- 126种药物中仅5种在CPIC指南和FDA表中有相同的基因-药物关联和剂量推荐。
临床怎么用
- 临床药学智能体应同时参考FDA表和CPIC指南,注意两者不一致性,避免单一来源误导剂量调整决策。
局限性
- 差异可能部分源于FDA拥有未发表文献中的药物基因组学信息,或分类基于临床可操作性以外的标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Healthcare professionals need a clear understanding of information about gene-drug interactions in order to make optimal use of pharmacogenetic (PGx) testing. In this report, we compare PGx information in the US Food and Drug Administration (FDA) Table of Pharmacogenetic Associations with information presented in Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. SUMMARY: Information from CPIC guidelines and the FDA Table of Pharmacogenetic Associations do not have a high level of concordance. Many drugs mentioned in CPIC guidelines are not listed in the FDA table and vice versa, and the same gene-drug association and dosing recommendation was reported for only 5 of the 126 drugs included in either source. Furthermore, classification of drugs in specific sections of the FDA table does not correlate well with CPIC-assigned or provisionally assigned clinical actionability levels. The Pharmacogenomics Knowledge Base (PharmGKB) clinical annotation levels are generally high for drugs mentioned in CPIC guidelines. PharmGKB clinical annotation levels are often unassigned or are lower level for drugs listed on the FDA table but not in CPIC guidelines. These differences may be due in part to FDA having access to PGx information that is unavailable in published literature and/or because PGx classifications are based on criteria other than clinical actionability. CONCLUSION: There are important differences between the PGx information presented in the FDA Table of Pharmacogenetic Associations and in CPIC guidelines. FDA and CPIC have different perspectives when evaluating PGx associations and use different approaches and information resources when considering clinical validity related to specific medicines. Understanding how information sources developed by each group differ and can be used together to form a holistic view of PGx may be helpful in increasing adoption of these information sources in practice.
引用
- Pritchard D, Patel JN, Stephens LE, et al. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines. Am J Health Syst Pharm. 2022. PMID: 35230418. doi:10.1093/ajhp/zxac064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。